Caralluma lasiantha is a succulent plant belongs to Ascalpedaceae family. The objective of this study was to evaluate and to compare the anti-hyperglycemic effect of Caralluma lasiantha with Chromium Picolinate on hyperglycemia induced by Cafeteria-Diet in Wistar albino rats. Hyperglycemia was induced in experimental rats by feeding Cafeteria-Diet for a study period of 90 days. Caralluma lasiantha (10, 20, and 40 mg/kg b.w.) & Chromium Picolinate (10 mg/kg b.w.) were administered orally once every day throughout the study and serum glucose levels were determined in different experimental days. Treatment with Caralluma lasiantha significantly reduced the serum glucose level in dose dependant manner. Data reveal an appreciated beneficial effect of Caralluma lasiantha on hyperglycemic rats. Caralluma lasiantha possesses anti-hyperglycemic effect, which promisingly support the use of Caralluma lasiantha as a food supplement or an adjunct treatment for hyperglycemia INTRODUCTION: Diabetes is increasing at an alarming rate worldwide, which can mainly be attributed to the sedentary life style and calorie-rich diet. Diabetes is often linked with abnormal lipid metabolism and is considered as a major factor for the development of atherosclerosis and cardiovascular complication. 1 Diabetes is a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia with disturbance of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action, or both. 2 Hyperglycemia is a common end point for all types of DM and it is an important parameter which can be assessed to evaluate the effectiveness of anti-diabetic drugs.

Background Bosutinib is a small molecule BCR-ABL, and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukaemia. According to published literature, no stability-indicating RP-HPLC method has been reported yet for estimation of bosutinib. Objective Hence, the stability-indicating RP-HPLC method has been developed for the stability study of bosutinib using risk and DoE-based enhanced analytical quality by design approach. Methods The risk-based analytical quality by design approach was applied by risk parameter identification and risk assessment by risk priority number (RPN) ranking and filtering method as per International Council for Harmonisation (ICH) Q9 guideline. The DoE-based AQbD approach was implemented by response surface analysis using a central composite design. The risk of critical method risk parameters was mitigated by navigation of design space and framing of control strategy. Results The chromatographic separation was performed using a C18 column and acetonitrile–1.0%, v/v triethylamine in water (pH 7.0 adjusted by ortho-phosphoric acid). The developed method was validated according to the ICH Q2 (R1) guideline.The developed and validated method was applied for the assay of bosutinib in pharmaceutical dosage forms. The developed method was extended for oxidative degradation kinetic study of bosutinib at different pH conditions. Conclusion The developed RP-HPLC method can be used as analytical tool for quality control and stability study of pharmaceutical dosage forms of bosutinib in pharmaceutical industry. Highlights Development and validation of Stability indicting RP-HPLC method for estimation of bosutinib by implementation of DoE and risk-based enhanced AQbD approach. Application of method for assay of pharmaceutical dosage forms and oxidative degradation kinetic study

No abstract

Pranlukast hydrate is an anti-asthmatic drug and used in the treatment of acute asthma. Stability-indicating RP-HPLC method for pranlukast hydrate has been developed and validated. The reverse phase high performance liquid chromatographic method was developed using Shimadzu Column: Kromosil 100 C18 (150 mm × 4.6 mm × 5 μm) and mobile phase Acetonitrile: 0.1% Glacial acetic acid (85: 15% v/v). Eluent was monitored with UV-detector at 262 nm with a flow rate of 0.5 mL/min, temperature maintained at 30°C. Stress testing was carried out in acidic, alkaline, oxidative, photolytic and dry heat degradation conditions. The method was validated as per the International Conference for Harmonization guidelines and includes specificity, accuracy, precision, linearity and limit of quantitation and detection parameters. A relative standard deviation <2% indicates the developed method was precise. The accuracy of the method was represented by recovery studies ranging between 99.41 and 99.72%. In acid, alkaline, oxidative stress conditions, pranlukast hydrate degrades significantly and in photolytic, dry heat, hydrolytic conditions remain stable. This proposed method is suitable for the analysis of pranlukast hydrate in its laboratory mixture.

Edoxaban Tosylate Monohydrate (EXN) is oral anticoagulant drug indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Sensitive and reproducible UV-Visible spectrophotometric method has been developed and validated for the estimation of Edoxaban Tosylate Monohydrate in its synthetic mixture. Methanol was used as a solvent. Developed method has been validated for linearity range, precision, accuracy, limit of detection, and limit of quantification as per ICH Q2(R1) guidelines. The method was found to be linear in the range of 5-25 μg/mL at λ max 289 nm and the regression coefficient value was found to be 0.9999. For Edoxaban LOD and LOQ values were found to be 0.654 μg/mL and 1.982 μg/mL. The method was successfully applied for estimation of Edoxaban Tosylate Monohydrate in its synthetic mixture and results were found to be in good agreement with the amount of Edoxaban Tosylate Monohydrate present in synthetic mixture.